Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol

与固定剂量传统合成DMARD和糖皮质激素的常规治疗相比，达标治疗策略更优：一项针对对常规合成DMARD和新型Certolizumab Pegol疗法反应不足的类风湿关节炎患者的多中心随机对照试验